Literature DB >> 11411802

FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes.

M Kaibori1, T Inoue, W Tu, M Oda, A H Kwon, Y Kamiyama, T Okumura.   

Abstract

Hepatic ischemia/reperfusion injury occurs in the clinical situations including liver transplantation. FK506 and cyclosporin A (CsA) are reported to be hepatotrophic agents in addition to being a powerful immunosuppressive agent. Studies were performed to determine whether the drugs influence a mitochondrial dysfunction under the hypoxic conditions in primary culture model of rat hepatocytes. The Anaeropack system was used for cell culture to create a hypoxia. Cells were treated with FK506 or CsA under the normoxic and hypoxic conditions. Hypoxia markedly decreased intracellular adenosine 5'-triphosphate (ATP) contents and the ketone body ratio (KBR, acetoacetate/beta-hydroxybutyrate) in culture medium as compared with normoxia. FK506 prevented the decreases of ATP contents and the KBR. In contrast, CsA had no effect on either ATP contents or the KBR. FK506, but not CsA, increased the KBR under the normoxic conditions. Under the hypoxic conditions, heat shock protein 70 (Hsp70) was detected after reoxygenation. FK506 enhanced the induction of Hsp70, but CsA again had no effect on Hsp70 induction. These results indicate that FK506 protects the hypoxia injury in part by preventing the mitochondrial dysfunction in concert with the enhancement of heat shock response in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411802     DOI: 10.1016/s0024-3205(01)01098-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice.

Authors:  Jing-Hua He; Hui-Na Zhang; Zhi-Bin Lin
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

2.  The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response.

Authors:  Alexa Klettner; Thomas Herdegen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

3.  Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion.

Authors:  Kwan-Hoon Moon; Brian L Hood; Partha Mukhopadhyay; Mohanraj Rajesh; Mohamed A Abdelmegeed; Yong-Il Kwon; Thomas P Conrads; Timothy D Veenstra; Byoung-Joon Song; Pal Pacher
Journal:  Gastroenterology       Date:  2008-06-25       Impact factor: 22.682

Review 4.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: analysis using mouse model and cultured cells.

Authors:  Kyoji Moriya; Hideyuki Miyoshi; Takeya Tsutsumi; Seiko Shinzawa; Hajime Fujie; Yoshizumi Shintani; Hiroshi Yotsuyanagi; Kohji Moriishi; Yoshiharu Matsuura; Tetsuro Suzuki; Tatsuo Miyamura; Kazuhiko Koike
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

6.  Rhinacanthus nasutus protects cultured neuronal cells against hypoxia induced cell death.

Authors:  James M Brimson; Tewin Tencomnao
Journal:  Molecules       Date:  2011-07-26       Impact factor: 4.411

Review 7.  A Potential Route to Reduce Ischemia/Reperfusion Injury in Organ Preservation.

Authors:  Marc Micó-Carnero; Mohamed Amine Zaouali; Carlos Rojano-Alfonso; Cristina Maroto-Serrat; Hassen Ben Abdennebi; Carmen Peralta
Journal:  Cells       Date:  2022-09-05       Impact factor: 7.666

8.  Mesenchymal stem cell-derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway.

Authors:  Zhuzhi Wen; Zun Mai; Xiaolin Zhu; Tao Wu; Yangxin Chen; Dengfeng Geng; Jingfeng Wang
Journal:  Stem Cell Res Ther       Date:  2020-01-23       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.